NCT03647020 (CLCG-ICSI) is a clinical trial in Pesticide Poisoning, sponsored by Centre Hospitalier Universitaire, Amiens.

Who is sponsoring NCT03647020?

NCT03647020 is sponsored by Centre Hospitalier Universitaire, Amiens.

What condition does NCT03647020 study?

NCT03647020 studies Pesticide Poisoning.

Is NCT03647020 still recruiting?

NCT03647020 is currently completed. Last updated 17 May 2023.

Last reviewed 2023-05-17 · How we verify

NCT03647020: CLCG-ICSI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Oocytes With CLCG on ICSI Outcomes and Their Potential Relation to Pesticide Exposure

Completed Last updated 17 May 2023

What this trial tests

trial in Pesticide Poisoning in 633 participants. Completed in 6 June 2017.

Timeline

1 January 2011

Primary endpoint
6 June 2017

6 June 2017

Quick facts

Lead sponsor	Centre Hospitalier Universitaire, Amiens
Status	Completed
Study type	OBSERVATIONAL
Enrollment	633
Start date	1 January 2011
Primary completion	6 June 2017
Estimated completion	6 June 2017

Conditions studied

Pesticide Poisoning — all drugs for Pesticide Poisoning →

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

18 and older, any sex, with Pesticide Poisoning. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oocyte quality is a key limiting factor in female fertility which is primarily reflected in morphological features. Centrally located cytoplasm granulation (CLCG) is one type of cytoplasmic dimorphism exhibited by oocytes that could be linked to pesticide exposure with a significant risk of decreased ICSI outcomes. This retrospective study included 633 women who were part of an intracytoplasmic spermatozoa injection (ICSI) program between 2009 and 2011. The participants lived in the Picardy region of France and had been exposed to pesticides. The participants were divided in two groups based on prevalence of oocytes with CLCG (LCLCG \[n= 83\]: low prevalence of oocytes with CLCG under 25%. HCLCG \[ n= 68\]: high prevalence of CLCG over 75%). The embryological and clinical outcomes were analysed for both groups and were calculated using the difference between the two values.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
NCT07071662 — Induction of Labor in Breech Presentation · completed
NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03647020 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
Last refreshed: 17 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03647020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing